Also from this source

You just read:

Apogenix' APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma

News provided by

Apogenix

Jan 13, 2014, 09:00 EST